MedTrace Logo

Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension

NCT02184858 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2018-09-20

No results posted yet for this study

Summary

This open label 4 month study will evaluate efficacy (blood pressure lowering effects) and safety of lisinopril in children 1-18y whose parents grant permission to participate. This dose titration study is being conducted to support the statement that personalized titration of lisinopril (based on blood pressure and renin-aldosterone ratio) can increase patient response.

Conditions

  • Primary Hypertension
  • Secondary Hypertension

Interventions

DRUG

lisinopril, ACE-inhibitor

Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment

Sponsors & Collaborators

  • University Ghent

    lead OTHER

Principal Investigators

  • Johan Vande Walle, PhD MD · Ghent University, Department of Pediatrics and Medical Genetics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-25
Primary Completion
2017-05-08
Completion
2018-09-17

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02184858 on ClinicalTrials.gov